Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B

Andrés Duarte-Rojo, E. Jenny Heathcote*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

49 Scopus citations

Abstract

Chronic hepatitis B (CHB) is prevalent worldwide. It may cause cirrhosis and hepatocellular carcinoma. Treatment for this condition may need to be lifelong, thus the drugs used must be both efficacious and safe. Clinical trials of tenofovir have demonstrated a good safety profile for this drug and it has potent antiviral properties. However, to better characterize the safety of this drug, the postmarketing surveillance must be taken into account. Clinicians need to be vigilant, as infrequent adverse events may be revealed during this phase. The current review presents a detailed exposé of preclinical and clinical data on tenofovir to increase awareness of possible adverse events and drug'drug interactions, based on the large experience of this drug in human immunodeficiency virus (HIV) treatment (and to date in patients with CHB). Several recommendations that may help the clinician to prevent the development of adverse events associated with tenofovir disoproxil fumarate (TDF) treatment are outlined, along with a suggested surveillance protocol for the timely and proper identification of possible renal and bone toxicity.

Original languageEnglish (US)
Pages (from-to)107-119
Number of pages13
JournalTherapeutic Advances in Gastroenterology
Volume3
Issue number2
DOIs
StatePublished - Mar 2010

Keywords

  • Adverse drug event
  • Drug interactions
  • Hepatitis B virus
  • Hypophosphatemia
  • Mitochondrial toxicity
  • Osteomalacia
  • Tenofovir
  • Treatment outcome

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B'. Together they form a unique fingerprint.

Cite this